Efficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis

被引:0
|
作者
Draelos, Zoe Diana [1 ]
Traub, Michael [2 ]
Gold, Michael H. [3 ]
Green, Lawrence J. [4 ]
Amster, Mark [5 ]
Barak-Shinar, Deganit [6 ]
Kircik, Leon H. [7 ,8 ,9 ,10 ]
机构
[1] Dermatol Consulting Serv PLLC, High Point, NC USA
[2] Hawaii Integrat Oncol Hoo Lokahi, Kailua, HI USA
[3] Tennessee Clin Res Ctr, Nashville, TN USA
[4] George Washington Univ, Sch Med, Washington, DC USA
[5] Metro Boston Clin Partners LLC, Boston, MA USA
[6] Kamedis Ltd, Tel Aviv, Israel
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[8] Indiana Univ, Med Ctr, Indianapolis, IN 46202 USA
[9] Physicians Skin Care PLLC, Louisville, KY 40217 USA
[10] DermRes PLLC, Louisville, KY 40241 USA
关键词
SKIN; PSORIASIS; BARRIER;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: The study was conducted to determine the efficacy of the botanical combination incorporated in Kamedis Eczema Therapy Cream (the test product) for children with mild to moderate atopic dermatitis. Design: The study was designed as an interventional, multi-center, double-blind, randomized, controlled study. Setting: Children subjects were a sub-population of the 108 combined population of adults and children evenly randomly divided into three treatment groups: test product, vehicle, and comparator. The vehicle used was the identical test product without the botanical combination while the comparator was a leading OTC brand in the US market. All three groups used the same Kamedis body wash followed by one of the three randomized treatment creams for the affected areas. Participants: Thirty-nine (39) children subjects with uncomplicated, stable, mild to moderate atopic dermatitis were recruited and qualified for the study, 24 female and 15 male, ages varying between 3 and 18. Measurements: Investigators assessed the severity of each subject using the Investigator Global Assessment (IGA), affected Body Surface Area (BSA) extent evaluated parameters at each of the visit days 0, 7 14, and 28. Subjective symptoms of pruritus and insomnia were evaluated by the patient or their legal guardian. The SCORAD and EASI indexes were calculated based on the collected parameters. Results: The test product demonstrated an improvement in all evaluated and calculated clinical parameters over the vehicle at the end of the treatment duration, proving the validation that the test product is much more effective and beneficial than the vehicle. The test product reached 40% of 'clear' IGA subjects out of the enrolled subjects and 60% out of the 'clear' and 'almost clear' IGA subjects comparing to 8% and 38%, respectively, with the vehicle, presenting a clear advantage over the vehicle. The BSA improvement comparison analysis of the test product over the vehicle yielded P value of less than 0.05, which is statistically significant. The SCORAD and EASI indexes also showed an advantage of the test product versus the vehicle at week 4. Conclusion: The study results validate that the botanical combination is the key factor for the efficacy and improvement of the AD symptoms within this population of children.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 50 条
  • [21] Beneficial effects of an alkaline topical treatment in patients with mild atopic dermatitis
    Jurecek, Ludovit
    Rajcigelova, Tana
    Kozarova, Andrea
    Werner, Tanja
    Vormann, Juergen
    Kolisek, Martin
    JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (09) : 2824 - 2831
  • [22] Efficacy and safety of topical calcineurin inhibitors in the treatment of atopic dermatitis
    Silny, Wojciech
    Czarnecka-Operacz, Magdalena
    PRZEGLAD DERMATOLOGICZNY, 2009, 96 (02): : 99 - 103
  • [23] Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis
    Abramovits, William
    Hung, Peter
    Tong, Kuo B.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2006, 7 (04) : 213 - 222
  • [24] Efficacy and Economics of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis
    William Abramovits
    Peter Hung
    Kuo B. Tong
    American Journal of Clinical Dermatology, 2006, 7 : 213 - 222
  • [25] Topical treatment of atopic dermatitis
    Boguniewicz, M
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2004, 24 (04) : 631 - +
  • [26] Treatment preferences among patients with mild-to-moderate atopic dermatitis
    Myers, Kelley
    Silverberg, Jonathan I.
    Parasuraman, Shreekant
    Pierce, Anna
    Eichenfield, Lawrence F.
    Poulos, Christine
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [27] New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
    de Lucas, Raul
    Garcia-Millan, Cristina
    Perez-Davo, Azahara
    Moreno, Esther
    Redondo, Pedro
    CHILDREN-BASEL, 2019, 6 (02):
  • [28] Patient assessment of desonide hydrogel for the treatment of mild to moderate atopic dermatitis
    Kerney, Donna
    Ford, Rosanne
    Gotz, Vinccnt
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB69 - AB69
  • [29] Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis
    Hebert, Adelaide A.
    CLINICAL THERAPEUTICS, 2006, 28 (12) : 1972 - 1982
  • [30] Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis
    Castelli, Gregory
    Schaffer, Monica
    AMERICAN FAMILY PHYSICIAN, 2018, 98 (06) : 379 - 380